Precision Medicine

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.

A new FAIR Health report finds 57.5% of commercially insured Americans have a chronic condition, with costs nearly doubling for patients with just one.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

After Amgen steps back, Kyowa Kirin takes full control of its promising atopic dermatitis drug, rocatinlimab, betting on its unique science.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

A Bolingbrook senior care provider earns a prestigious certification, adopting an evidence-based framework that promises a new level of personalized care.

With a key nod from NCCN guidelines and strong clinical data, high-resolution micro-ultrasound is now a powerful, accessible alternative to MRI.

The FDA has qualified MolecuLightDX's measurement tool, a move set to standardize clinical trials, accelerate innovation, and redefine wound healing.

The new SecureFlex™ device aims to improve tissue sampling for diseases like pancreatic cancer, enabling more precise diagnoses and personalized treatments.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.

Myriad Genetics is launching a new cancer test that promises to detect recurrence earlier than ever. But can it win in a competitive market?

An oral drug for Huntington's disease shows early success, improving patient scores where a decline was expected, fueling hope for a breakthrough treatment.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

A new study confirms AI can detect major heart conditions from one brief ultrasound clip, empowering any clinician to perform life-saving cardiac screening.